Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Diversify Advisory Services LLC

Diversify Advisory Services LLC cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,699 shares of the medical research company’s stock after selling 1,877 shares during the quarter. Diversify Advisory Services LLC’s holdings in Edwards Lifesciences were worth $1,502,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $29,000. Webster Bank N. A. acquired a new position in Edwards Lifesciences in the second quarter valued at $39,000. Versant Capital Management Inc grew its position in Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the period. Finally, HHM Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $55,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on EW. Canaccord Genuity Group dropped their target price on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Truist Financial decreased their price target on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research report on Friday, October 25th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, Piper Sandler decreased their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Fifteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $69.37 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm’s 50-day simple moving average is $68.10 and its 200-day simple moving average is $77.99. The firm has a market cap of $41.80 billion, a PE ratio of 29.90, a price-to-earnings-growth ratio of 3.00 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Co. will post 2.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,099,238 over the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.